NCT/Study#
N/A /
RW-SURVIVAL-HER2
Real-World Survival Among Patients with HER2-Positive and HER2-Low Metastatic Malignancies Who Received HER2-Targeting Agents
DISEASE GROUP:
Breast Cancer Clinical Trials
current phase:
N/A
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
